Zydus Lifesciences Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

Zydus Lifesciences and Sunshine Healthcare today announced the setting up of a strategic joint venture company ? Zydus Sunshine Lifesciences, with an investment commitment of over USD 20 million to establish a pharmaceutical manufacturing facility in Sri Lanka, strengthening local production and reducing import dependence.

The facility, to be located at the Board of Investment zone in Horana, will be developed on nearly four acres of land. The foundation stone was laid today, marking the formal commencement of the project. The plant will focus on manufacturing pharmaceutical products for Sri Lanka's retail market, improving access to high-quality medicines while supporting national supply chain resilience.

The joint venture combines Zydus' global expertise in pharmaceutical manufacturing and technical know-how with Sunshine's strong local market presence and healthcare distribution capabilities. The partnership will support technology transfer, build local manufacturing capability, and create employment, contributing to the long-term development of Sri Lanka's healthcare ecosystem. The initiative comes at a critical time as Sri Lanka prioritises domestic production in essential sectors. By strengthening local pharmaceutical manufacturing capacity, the venture is expected to enhance supply security, reduce reliance on imports, and improve the affordability and availability of medicines.

Zydus Lifesciences has received a Warning Letter from the United States Food and Drug Administration (USFDA) relating to its formula on manufacturing facility located at Baddi, Himachal Pradesh.

The Warning Letter was issued in response to a request for records pursuant to sec on 704(a)(4) of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any onsite inspection of the facility by the USFDA. The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.

The company added that the said Warning Letter will not impact current operations and supplies from the Baddi site.

The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025. Subsequent to the conclusion of the inspec on, the Company received the Establishment Inspection Report (EIR) in October 2025, with the final compliance status classified as Voluntary Ac on Indicated (VAI).

The warning letter was issued in response to a request for records pursuant to a section of the Federal Food, Drug, and Cosmetic Act, and does not pertain to any on-site inspection of the facility by the US FDA.

The communication references technical observations regarding the use of purified talc that did not meet the current United States Pharmacopeia (USP) requirements.

We believe that the said warning letter will not impact current operations and supplies from the Baddi site,? Zydus Lifesciences said in a statement.

The Baddi manufacturing facility was last subjected to an on-site inspection by the USFDA in August 2025.

Subsequent to the conclusion of the inspection, the company received the establishment inspection report (EIR) in October 2025, with the final compliance status classified as voluntary action indicated (VAI).

Zydus Lifesciences is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company?s consolidated net profit jumped 8.68% to Rs 1,272.5 crore on 16.22% increase in revenue from operations to Rs 7,587 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News

Zydus Lifesciences Ltd rose for a fifth straight session today. The stock is quoting at Rs 1105.45, up 1.81% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.24% on the day, quoting at 23849.9. The Sensex is at 75777.13, down 0.12%. Zydus Lifesciences Ltd has added around 23.94% in last one month.

Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has added around 6.44% in last one month and is currently quoting at 24716, up 0.2% on the day. The volume in the stock stood at 14.03 lakh shares today, compared to the daily average of 23 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1114.05, up 2.08% on the day. Zydus Lifesciences Ltd is up 18.87% in last one year as compared to a 3.64% fall in NIFTY and a 15.5% fall in the Nifty Pharma index.

The PE of the stock is 29.59 based on TTM earnings ending March 26.

Powered by Capital Market - Live News